Overview

Efficacy of Ketorolac 0.4% in Prostaglandin Suppression

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
A pilot study to evaluate the extent of PGE2 inhibition (mean aqueous values) by Ketorolac 0.04% following peripheral iridotomy
Phase:
Phase 4
Details
Lead Sponsor:
Allergan
Treatments:
Ketorolac
Ketorolac Tromethamine
Lubricant Eye Drops
Ophthalmic Solutions